Brawn Biotech FY26 annual report: revenue up 26%, loss narrows

Revenue Growth 20pctPat NegativeResults View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+4.5%Reaction day

₹22.00

prior close

—

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.6%+5.1% vs market

Pharmaceuticals peers, median of 171sector-0.2%+4.8% vs sector

On the reaction day the stock moved 5.1 pts more than Nifty Microcap 250 and 4.8 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

—

10m

—

15m

—

30m

—

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+4.5-0.6+5.1-0.2+4.8

Next day

+2.7+0.0+2.7+0.2+2.5

+3.2+0.7+2.5+0.1+3.1

+6.4+1.1+5.3+0.6+5.8

+6.4+1.6+4.7+0.8+5.6

+5.9+1.5+4.4+0.0+5.8

+0.6+1.4-0.8+0.5+0.1

15d

-2.3+0.4-2.7+0.8-3.2

+11.4-1.4+12.8-2.1+13.5

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 171Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Brawn Biotech posted FY26 revenue of Rs 16.98 crore, up 26% from Rs 13.46 crore in FY25. Loss after tax narrowed to Rs 94.06 lakh from Rs 1.74 crore. No dividend due to losses. The 41st AGM is on Sept 29, 2026 via video conferencing. Shareholders vote on reappointing director Brij Raj Gupta, appointing M/s G D S M and Co as new statutory auditor, and approving manager remuneration of Rs 9.77 lakh per annum for Amit Kumar.

Likely market impact

Revenue recovering but company still loss-making, no dividend, new auditor proposed, shareholders to vote on key items at AGM on Sept 29, 2026.